Cite
HARVARD Citation
Kwakman, J. et al. (n.d.). Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group. European journal of cancer. pp. S5-. [Online].